The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention relates to the field of cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) a genetically engineered to express chimeric antigen receptor (CAR) polypeptides to produce CAR-TILs that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed CAR-TILs.

The present invention provides tumor-derived extracellular vesicles (EVs) lacking an immune suppressive factor, for example, miR-424, methods of making and methods of use for treating cancer. Further the present invention provide vaccine compositions comprising modified tumor-derived EVs for use in treating secondary tumors.

Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.

The invention relates to the field of cancer, in particular uterine cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the ARID1A, KMT2B, KMT2D, PIK3R1, and PTEN genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a neoantigen-based vaccine composition and a long acting, IL-2RPβ-selective agonist composition comprised of compounds of Formula (I), and optionally, an anti-PD-1 antibody.

The present invention relates to improved strategies, compositions, and methods for producing shared neoplasia vaccines, including “off the shelf” pre-furnished shared neo-epitope warehouses, which can be used to enable the rapid production of bladder cancer neoantigen-based vaccines. The present invention relates to identified and designed shared neo-epitopes based on non-synonymous mutations that are present in at least 1% of subjects having bladder cancer. The strategies, compositions, and methods include the identification of neo-epitopes that are known or determined (e.g. predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) and exclusion of such identified neo-epitopes that are known or determined (e.g. predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) from the shared neo-epitopes that are to be used in the shared neoantigen-based vaccines.

Provided herein are methods and compositions related to bacteria of genus Burkholderia useful as therapeutic agents.

The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.